Peptide as absorption enhancer and composition containing same
AssigneeSoonchunhyang University Industry Academy Cooperation Foundation
InventorKeon-Hyoung Song
Life of this patent
Estimating the term…
Abstract
As described herein, an peptide of SEQ ID NO: 1 is modified at the terminal end. Specifically, the carboxyl-group of the leucine at the terminal end of the amino acid sequence FCIGRL (SEQ ID NO: 1) is modified with a —CONH2. This modified peptide is used as a permeation enhancer to boost the mucous membrane permeation, thereby noticeably increasing the bioavailability of a drug that is administered together with the modified peptide. The drug to be administered with the modified peptide can be cyclosporine A.
Claims18
A composition for enhancing mucous membrane permeability, the composition comprising an amino acid sequence FCIGRL (SEQ ID NO:1), wherein the carboxyl group (—COOH) of Leucine at the terminal end of the amino acid sequence is modified into —CONH2;
- and
- an active component, wherein the active component is not linked to the peptide.
A preparation comprising:
- a peptide having an amino acid sequence FCIGRL (SEQ ID NO:1), wherein the carboxyl group (—COOH) of Leucine at the terminal of the amino acid sequence is modified into —CONH2;
- and
- an active component, wherein the active component is cyclosporine A and is not linked to the peptide.
A method of enhancing permeation of an active component through mucous membranes in a subject comprising administering to a subject in need thereof an active component and a peptide respectively,
- wherein the peptide has an amino acid sequence FCIGRL (SEQ ID NO:1) wherein the carboxyl group (—COOH) of Leucine at the terminal end of the amino acid sequence is modified into —CONH2 and the peptide boosts the mucous membrane permeation of the active component, and
- the active component is a cyclosporine A and is not linked to the peptide.
Dependencies are inferred from the claim text.